MX2022001013A - Degradador selectivo del receptor de estrogeno. - Google Patents

Degradador selectivo del receptor de estrogeno.

Info

Publication number
MX2022001013A
MX2022001013A MX2022001013A MX2022001013A MX2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
selective estrogen
receptor degrader
chromen
enyl
Prior art date
Application number
MX2022001013A
Other languages
English (en)
Inventor
Jayraj Dilipbhai Aradhye
Bhavesh Mohanbhai Panchal
Biswajit Samanta
Ranjan Kumar Pal
Trinadha Rao Chitturi
Sandeep Pankajkumar Pathak
Kaushik Dhanjibhai Prajapati
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2022001013A publication Critical patent/MX2022001013A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un degradador selectivo del receptor de estrógeno (SERD), un compuesto 3-(3,5-difluorofenil)-2-[4-[(E)-3-[3-(fluorometil)azetid in-1-il]prop-1-enil]fenil]-4-metil-2H-cromen-7-ol y su enantiómero S, (2S)-3-(3,5-difluorofenil)-2-[4-[(E)-3-[3-(fluorome til)azetidin-1-il]prop-1-enil]fenil]-4-metil-2H-cromen-7-ol, o sales farmacéuticamente aceptables de estos. También se proporcionan procesos para su preparación. También se proporciona el uso de estos compuestos para el tratamiento de enfermedades relacionadas con la modulación de los receptores de estrógeno, tales como el cáncer de mama positivo para ER.
MX2022001013A 2019-07-22 2020-07-22 Degradador selectivo del receptor de estrogeno. MX2022001013A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921029554 2019-07-22
PCT/IB2020/056914 WO2021014386A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Publications (1)

Publication Number Publication Date
MX2022001013A true MX2022001013A (es) 2022-02-22

Family

ID=71842730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001013A MX2022001013A (es) 2019-07-22 2020-07-22 Degradador selectivo del receptor de estrogeno.

Country Status (14)

Country Link
US (2) US11014915B2 (es)
EP (1) EP4003525A1 (es)
JP (1) JP2022541938A (es)
KR (1) KR20220046586A (es)
CN (1) CN114302879A (es)
AU (1) AU2020317099A1 (es)
BR (1) BR112022001285A2 (es)
CA (1) CA3148592A1 (es)
CL (1) CL2022000156A1 (es)
IL (1) IL290036A (es)
MX (1) MX2022001013A (es)
PE (1) PE20221588A1 (es)
WO (1) WO2021014386A1 (es)
ZA (1) ZA202201157B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3148592A1 (en) * 2019-07-22 2021-01-28 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
WO2023150056A1 (en) * 2022-02-01 2023-08-10 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
EP0470310B1 (en) 1990-08-09 1995-11-29 Council of Scientific and Industrial Research Novel benzopyrans and process for their production
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
WO1999002512A1 (en) 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
ES2627692T3 (es) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
CA2857061A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
MX2015017655A (es) 2013-06-19 2016-04-15 Seragon Pharmaceuticals Inc Modulador de receptores de estrogeno y uso del mismo.
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN103879283B (zh) * 2014-03-10 2019-01-15 浙江吉利汽车研究院有限公司 一种电动车辆
JP2017538727A (ja) * 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療に有用な２，３−ジフェニルクロメンの誘導体
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
RS63217B1 (sr) * 2015-10-27 2022-06-30 Sun Pharma Advanced Res Co Ltd Novi heterociklični antiestrogeni
CA3148592A1 (en) * 2019-07-22 2021-01-28 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader

Also Published As

Publication number Publication date
US11014915B2 (en) 2021-05-25
CA3148592A1 (en) 2021-01-28
BR112022001285A2 (pt) 2022-03-22
CL2022000156A1 (es) 2022-11-18
CN114302879A (zh) 2022-04-08
IL290036A (en) 2022-03-01
AU2020317099A1 (en) 2022-02-24
WO2021014386A1 (en) 2021-01-28
KR20220046586A (ko) 2022-04-14
ZA202201157B (en) 2023-07-26
JP2022541938A (ja) 2022-09-28
EP4003525A1 (en) 2022-06-01
US20210024504A1 (en) 2021-01-28
US20210261534A1 (en) 2021-08-26
PE20221588A1 (es) 2022-10-10

Similar Documents

Publication Publication Date Title
MX2022001013A (es) Degradador selectivo del receptor de estrogeno.
IL287945A (en) Compounds for the treatment of Huntington's disease
EA201792394A3 (ru) Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
TNSN08306A1 (fr) Imidazoles substitutes et leur utilisation comme pesticides
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
PE20020917A1 (es) Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato
ZA202301275B (en) Indole compounds as androgen receptor modulators
TN2011000664A1 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
MX2018012619A (es) Derivados de bisfenol y su uso como moduladores de la actividad del receptor de androgeno.
MX2007004862A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias.
EA201690391A1 (ru) Селективные модуляторы рецептора сфингозин-1-фосфата и способы хирального синтеза
WO2008144483A3 (en) Agents for treating disorders involving modulation of ryanodine receptors
WO2020081410A3 (en) Radioligands for imaging the lpa1 receptor
BRPI0610907A2 (pt) composto ou precursores hidrolisÁveis in vivo ou sal farmaceuticamente aceitÁvel do mesmo, mÉtodos de tratamento ou profilaxia de uma doenÇa ou condiÇço na qual a modulaÇço do receptor de mch1 É benÉfica e de tratamento ou profilaxia de doenÇas, composiÇço farmacÊutica, e, uso de um composto
JO3493B1 (ar) صيغ صيدلانية
EA201290329A1 (ru) Селективные гетрероциклические модуляторы рецептора сфингозин-1-фосфата
BR112021022216A2 (pt) Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
SA520420382B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1
MX2007011280A (es) Dipirazoles como farmacos del sistema nervioso central.
MX2020008523A (es) Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5).
HK1106494A1 (en) Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
MX2021002109A (es) Pirrolo [2,3-b] piridina 4-sustituida como moduladores erbb utiles para tratar el cancer.
MX2021007687A (es) Sales novedosas de degradadores selectivos de receptores de estrogeno.
MA45665B1 (fr) Dérivés d'éthynyle